



Press release  
Paris, July 28th, 2022

---

## Mayoly Spindler completes the acquisition of Ipsen's CHC branch

---

Today, Mayoly Spindler announced it has completed the acquisition of Ipsen's CHC (Consumer Healthcare) branch. The portfolio acquired as part of this transaction includes internationally renowned brands such as Smecta®, Forlax®, Fortrans® and Tanakan®, which are recognized by practitioners and patients all over the world and distributed in more than 100 countries.

This acquisition is aligned with Mayoly Spindler's development strategy in consumer healthcare. A French, family-owned and independent pharmaceutical group, Mayoly Spindler seeks to become a reference company in Gastroenterology and Dermo-cosmetics. With strong brands such as Meteospasmyl®, Probiolog® or Topicrem®, Mayoly Spindler pursues its growth momentum and aims to become a major player in the OTC market, and more broadly in Consumer Healthcare, within the next decade.

With 2,200 employees across all continents, the combined entity will have a strong industrial footprint in France, with well-known brands on an international level, in complementary therapeutic areas and with strong commercial excellence, to continue its development in the medicines, consumer healthcare, dermo-cosmetic and diagnostic market segments. The pro forma net sales of the combined business are expected to reach 500 million euros in 2022, of which 65% outside France.

The historical ties and similar corporate cultures (family-owned businesses, French origins, shared values and human mindset...) that bring Mayoly Spindler and the Ipsen CHC branch together will be key in delivering a smooth integration and the development of the new entity, which is set to accelerate its growth, as it leverages strong brands, innovation, geographical expansion, commercial excellence and its team members strengths and qualities. This development will be achieved through a strong corporate social and environmental responsibility policy.

*"Combining our two French pharmaceutical companies, with family origins, a deeply anchored industrial culture with renowned expertise, will pave the way for our shared ambition to become a global reference in the consumer healthcare industry. Joining our scientific and medical expertise, as well as our commercial excellence and manufacturing skills, we are committed to making a difference to the daily lives of our patients and customers, by providing safe, effective and affordable healthcare solutions all over the world",* commented Jean-Nicolas Vernin, Chairman, and Nicolas Giraud, CEO of Mayoly Spindler.

As part of the transaction, as previously announced, Capza (through its Flex Equity Mid Market 2 fund) and Caravelle, two French and European financial partners with substantial experience in regard to operations of this scale, have acquired a minority stake in the combined entity.

*"We are particularly pleased to support this ambitious growth project in an industry we understand well, and thereby contribute to the creation of a national champion in consumer healthcare",* commented Lorène Martel, President of Caravelle, and Guillaume Basquin, Partner

of Capza Flex Equity Mid Market.

\*\*\*

### **Contacts**

Jean-Benoit Harel / [jean-benoit.harel@vae-solis.com](mailto:jean-benoit.harel@vae-solis.com) / +33 7 60 84 52 72

Alexis de Maigret / [alexis.demaigret@vae-solis.com](mailto:alexis.demaigret@vae-solis.com) / + 33 6 13 62 38 23

\*\*\*

### **About Mayoly Spindler**

Founded in 1909, Mayoly is an independent French and international pharmaceutical company specialising in Gastroenterology and Dermo-cosmetics.

Following the integration of Ipsen Consumer Healthcare, the combined Company employs over 2,200 people worldwide and will generate proforma net sales of €500m in 2022, 65% of which will be generated internationally in more than 100 countries. By 2027, Mayoly Group aims to reach over 600m€ sales and become a global reference in consumer health care.

Mayoly is a French industrial player committed to supporting patients, every day, in their well-being and health.

For more information, visit [www.mayoly-spindler.en](http://www.mayoly-spindler.en) or follow us on [LinkedIn](#).

### **About Ipsen CHC**

Ipsen's purpose in consumer healthcare is to bring people across the world care and comfort in their daily lives with healthcare solutions they can trust. Ipsen Consumer HealthCare develops and markets a wide range of innovative solutions - drugs, medical devices and probiotics - in four therapeutic areas: gastroenterology, cognitive disorders, pain, cough and cold. Ipsen Consumer HealthCare is present in 80 countries and employs 1,200 people.

### **About Capza**

CAPZA<sup>1</sup> is an established European private investment platform in private equity and private debt in SMEs since 2004. With €7 billion in assets under management<sup>2</sup>, CAPZA puts its experience and passion for business development at the service of institutional investors in Europe and worldwide through a platform of six complementary areas of expertise. CAPZA offers financing solutions to small & mid cap companies at every stage of their development. Its unique platform allows CAPZA to support companies over the long term by providing them with flexible financing solutions. Convinced that value creation now depends on the implementation of sustainable development strategies, CAPZA supports its portfolio companies in their transformation processes and ESG issues. As a generalist, CAPZA is particularly invested in companies in the technology, health and business services sectors.

The CAPZA group has more than 90 employees in Paris, Munich, Madrid and Milan.

More information: <https://capza.co> Twitter : @capza\_co

<sup>1</sup> Atalante (trade name CAPZA)

<sup>2</sup> Of which assets advised by Artemid SAS and managed by a third party - based on valuations as at 31/03/2022 and taking into account fundraising until 30/06/2022.

Team : Guillaume Basquin, Thibault Chatagnon, Roxane Pauquet

### **About Caravelle**

Caravelle is a family-owned diversified group that invests in Industry and Services. The Group seeks to provide long-term support to its investments in their organic and external growth strategies at national and international level. Caravelle has already supported companies in the healthcare sector (notably Cooper, between 2000 and 2016) and remains very active in this sector by accompanying, as an investor, its profound transformations: artificial intelligence, digitalisation of the patient pathway, or the rise of telemedicine, notably at Visionix (ophthalmological diagnostic equipment).

Team: Lorène Martel, Charles Vilgrain, Edouard de Beaufort, Thomas de Metz